Concord Biotech recently completed a significant block deal worth INR 31.1 crore, with each of the approximately 290,728 shares trading at INR 1,070. This indicates strong investor interest in the biotech company.

Concord Biotech has purchased Celliimune Biotech for approximately $940,000 to strengthen its research efforts in the field of DNA engineering for cancer treatments. The move aims to accelerate advancements in cancer therapeutics.